SCHEMBL7123956

SCHEMBL7123956

Cc1c(OCC2CCC2)c2cc(F)ccc2[nH]c1=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 3/20 0.41
PARP10 Q53GL7 3/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
PDE2A O00408 2/20 0.41
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
DRD2 P14416 1/20 0.36
SLC6A4 P31645 1/20 0.36
HTR2B P41595 1/20 0.36
PARP1 P09874 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7114808 0.87 PARP15 (0.43) PARP15PARP10KEAP1NFE2L2PDE2A
SCHEMBL7117395 0.86 PARP15 (0.40) PARP15PARP10KEAP1NFE2L2PDE2A
SCHEMBL7114952 0.86 PARP15 (0.40) PARP15PARP10KEAP1NFE2L2PDE2A
SCHEMBL7116504 0.84 TSHR (0.42) PARP15PARP10KEAP1NFE2L2PDE2A
SCHEMBL7115553 0.82 PARP15 (0.37) PARP15PARP10KEAP1NFE2L2PDE2A
SCHEMBL7114257 0.76 TLR9 (0.34) PARP15PARP10DRD2SLC6A4HTR2B
SCHEMBL7113422 0.75 BCHE (0.38) PARP15PARP10KDM4EALDH1A1HSD17B10
SCHEMBL2680943 0.73 MAOA (0.50) PDE2ARAB9ASLC6A4
SCHEMBL7121233 0.72 SIRT1 (0.42) PARP15PARP10PDE2AALDH1A1SLC6A4
SCHEMBL7123048 0.72 LMNA (0.41) PARP15PARP10PDE2AALDH1A1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US claimed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP claimed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO claimed
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 PARP15 616/4885PARP10 1080/4885KEAP1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.